Sodium-Glucose Cotransporter-2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis After Orthotopic Heart Transplant in a Prediabetic Patient: A Case Report

•This study highlighted a rare postoperative complication after heart transplantation.•We emphasized the challenges of perioperative management for heart transplantation.•The findings encouraged careful use of sodium-glucose cotransporter-2 inhibitors for patients awaiting heart transplantation. Pos...

Full description

Saved in:
Bibliographic Details
Published in:Transplantation proceedings 2021-10, Vol.53 (8), p.2636-2639
Main Authors: Cha, Beda M., Davoudi, Roland, DiVita, Michael C., Fan, Ashley M., Kamath, Megan Y.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•This study highlighted a rare postoperative complication after heart transplantation.•We emphasized the challenges of perioperative management for heart transplantation.•The findings encouraged careful use of sodium-glucose cotransporter-2 inhibitors for patients awaiting heart transplantation. Postoperative euglycemic diabetic ketoacidosis (euDKA) associated with sodium-glucose cotransporter-2 (SGLT2) inhibitor use has been well-documented and carries a Food and Drug Administration recommendation to hold SGLT2 inhibitors 3 to 4 days before a planned surgical procedure. Unfortunately, many surgical procedures, such as orthotopic heart transplant (OHT), are unplanned and unpredictable. With the increasing use of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, new challenges in patient management and perioperative risk have arisen. We report a case in which SGLT2 inhibitor–associated euDKA complicated the postoperative course of a prediabetic patient who had undergone OHT.
ISSN:0041-1345
1873-2623
DOI:10.1016/j.transproceed.2021.08.017